Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
NeurAxis (NRXS) Slides -46% Over 30 Days Despite 150% Revenue Growth

NeurAxis (NRXS) Slides -46% Over 30 Days Despite 150% Revenue Growth

Key Takeaways

  • NeurAxis (NRXS) fell roughly 46% over the last 30 days, sliding from about $7.92 to $4.27, despite reporting 150% year-over-year revenue growth.
  • The decline accelerated after third-quarter 2026 results showed a net loss that more than tripled, driven largely by a non-cash stock-compensation charge and rising commercial spending.
  • Ongoing share dilution and cash burn outweighed an improving top line, as the share count grew more than 40% year over year.
  • A new Category I CPT reimbursement code effective January 1, 2026 has structurally lifted average selling prices and gross margin, a key longer-term tailwind.
  • Over the last quarter the stock is down about 32%, reflecting a rally through September and October followed by a sharp November reversal.
  • The shares trade below their 50-day and 200-day moving averages, while the analyst consensus price target remains near $11.
  • For additional detail on valuation, results, and expectations, explore NeurAxis's Price Targets, Earnings, and Forecast pages.
  • Explore Trending AI Robots to see how AI-driven trading bots evaluate tickers like NRXS.

Company Background and Market Position

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic gastrointestinal conditions, particularly disorders of the gut-brain interaction in both children and adults. Its main product, IB-Stim, is a percutaneous electrical nerve field stimulation device cleared for patients aged eight and older dealing with functional abdominal pain tied to irritable bowel syndrome, functional dyspepsia, and related nausea. The company also offers RED, a diagnostic tool for assessing neuromuscular function and rectal hypersensitivity. Listed on the NYSE American under the symbol NRXS, it draws investor interest due to its position in an under-penetrated pediatric GI market and growing insurance coverage.

Recent Stock Performance: 30 Days and the Broader Quarter

Over the last 30 days, NRXS declined approximately 46%, moving from a closing price near $7.92 down to roughly $4.27. This was a gradual erosion through November rather than one sharp drop, with several sessions showing higher volume as selling intensified. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Looking at the last quarter provides more context. Starting from around $6.27 three months earlier, the shares advanced through September and October, hitting an intraday high near $8.05 before reversing in November. That leaves the stock down about 32% over the full three-month stretch, with the earlier autumn gains fully erased after the third-quarter update.

Key Drivers Behind the 30-Day Move

The main trigger was the third-quarter 2026 earnings release. NeurAxis reported revenue of about $2.03 million, up 150% year over year, with gross margin around 86.6% and an average selling price near $1,045 per device. Yet the net loss more than tripled to roughly $6.55 million, largely from a sizable non-cash stock-compensation expense and higher spending on commercial and clinical efforts.

Investor focus stayed on the balance sheet and share count rather than the revenue line. Shares outstanding increased more than 40% year over year as equity was issued to support operations, which diluted per-share value even while revenue grew. With cash in the low single-digit millions and ongoing operating losses, attention turned to cash burn rates and whether growth could keep pace with dilution. The technical break below key moving averages added to the pressure.

Quarterly Context and Reimbursement Tailwinds

The three-month picture shows a business with structural improvements running into financing questions. The January 1, 2026 launch of a permanent Category I CPT code for IB-Stim created a clearer reimbursement path, expanding payer coverage and supporting better pricing and volumes. This helped fuel revenue gains and lifted the stock through the fall. From what I see, the new code remains a meaningful longer-term positive.

Still, the funding approach stayed dilutive, and the earnings report highlighted the gap between revenue growth and bottom-line results. As the sales team expanded and clinical work advanced, expenses outpaced revenue on a GAAP basis. The quarter’s pullback reflects investors weighing how quickly reimbursement gains can deliver sustainable per-share value.

Factors to Monitor Going Forward

Several elements will influence the path ahead. Reimbursement progress stays central, including further adoption of the Category I CPT code, new payer decisions, and movement on the Veterans Administration channel. Management has also noted plans to start a large multi-center adult study for functional dyspepsia, which could expand the market over time.

Financially, attention will likely stay on cash use, share-count trends, and whether operating leverage improves as the commercial organization matures. Future quarterly reports and any capital raises will be important checkpoints. I’m watching this closely because these elements carry real risk alongside the growth outlook.

Using Tickeron AI Tools for Deeper Analysis

One resource I turn to when assessing names like this is Tickeron’s AI Trading Bots. These automated strategies draw from a broad set of models monitoring thousands of tickers and can highlight how different approaches are currently positioned, offering another layer of perspective alongside traditional research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NRXS

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for NRXS turns negative, indicating new downward trend

NRXS saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 68 similar instances where the indicator turned negative. In 64 of the 68 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 27 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

NRXS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NRXS crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for NRXS entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 123 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.641) is normal, around the industry mean (3.596). P/E Ratio (-8.211) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -7%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
11611 North Meridian Street
Phone
+1 812 689-0791
Employees
24
Web
https://www.neuraxis.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.